Teva, Glenmark to pay $255 million to resolve DOJ price-fixing claims
Teva Pharmaceuticals and Glenmark Pharmaceuticals reached deferred prosecution agreements with the Department of Justice to resolve antitrust claims over a generic drug price-fixing cartel....To view the full article, register now.
Already a subscriber? Click here to view full article